

# Human TNF $\alpha$ ELISA Kit

Instructions for use

Catalogue numbers:	1x48 tests:	950.090.048
	1x96 tests:	950.090.096
	2x96 tests:	950.090.192

**For research use only**

Fast Track Your Research.....

## Table of Contents

1. Intended use .....	2
2. Introduction .....	2
2.1. Summary .....	2
2.2. Principle of the method .....	3
3. Reagents provided and reconstitution .....	4
4. Materials required but not provided .....	4
5. Storage Instructions .....	5
6. Specimen collection, processing & storage .....	5
7. Safety & precautions for use .....	6
8. Assay Preparation .....	7
8.1. Assay Design .....	7
8.2. Preparation of Wash Buffer .....	7
8.3. Preparation of Standard Diluent Buffer 1X .....	7
8.4. Preparation of Standard .....	8
8.5. Preparation of Control .....	8
8.6. Preparation of Biotinylated Anti-TNF $\alpha$ .....	8
8.7. Preparation of Streptavidin-HRP .....	9
9. Method .....	10
10. Data Analysis .....	11
11. Assay limitations .....	11
12. Performance Characteristics .....	12
12.1. Sensitivity .....	12
12.2. Specificity .....	12
12.3. Precision .....	12
12.4. Dilution Parallelism .....	13
12.5. Spike Recovery .....	13
12.6. Stability .....	13
12.7. Expected serum values .....	13
12.8. Standard Calibration .....	13
13. Bibliography .....	14
14. Diaclone Human TNF $\alpha$ ELISA references .....	14
15. Assay Summary .....	17

# Human TNF $\alpha$ ELISA KIT

## 1. Intended use

The Diaclone Human TNF $\alpha$  ELISA kit is a solid phase sandwich ELISA for the *in-vitro* qualitative and quantitative determination of TNF $\alpha$  in supernatants, buffered solutions or serum and plasma samples. This assay will recognise both natural and recombinant human TNF $\alpha$ .

**This kit has been configured for research use only. Not suitable for use in therapeutic procedures.**

## 2. Introduction

### 2.1. Summary

Tumor Necrosis Factor (TNF $\alpha$ ), also known as cachectin, is a polypeptide cytokine produced by monocytes and macrophages. It functions as a multipotent modulator of immune response and further acts as a potent pyrogen (4, 17). TNF $\alpha$  circulates throughout the body responding to stimuli (infectious agents or tissue injury), activating neutrophils, altering the properties of vascular endothelial cells, regulating metabolic activities of other tissues, as well as exhibiting tumoricidal activity by inducing localized blood clotting. TNF $\alpha$  also inhibits lipoprotein lipase activity resulting in cachexia, a physical wasting condition (4, 17). Activation of B-cells by the Epstein Barr virus can be inhibited by TNF $\alpha$  (15). Due to its varied actions throughout the immune system, TNF $\alpha$  may play a role in the pathogenesis of many disease states.

TNF- $\alpha$  production is mediated by the action of lymphokines and endotoxins on the macrophage. Purified monocytes produce TNF $\alpha$  within four hours of stimulation by recombinant IL-2 (9) and there is some *in vitro* evidence to suggest that TNF $\alpha$  is expressed at high levels and with prolonged kinetics in T cells stimulated by both CD2 and CD28 (5). Secretion of TNF $\alpha$  is enhanced by gamma interferon. TNF $\alpha$  then induces or enhances the specific production of Class I MHC antigen, GM-CSF, and IL-1. Recent evidence has suggested an intracellular role for this peptide (23).

TNF $\alpha$  may play a significant role in the pathogenesis of inflammatory disease of the joints and other tissues. Chin et al. (6) found that TNF $\alpha$ , along with gamma interferon and IL-1 increased cell surface expression of ICAM-1 on synovial fibroblasts. Alvaro-Garcia et al. (3) reported that TNF $\alpha$  stimulates synovial proliferation.

Waage et al. (25) found that increased levels of TNF $\alpha$  in patients with septicemia and meningococcal disease correlated with fatal outcome. Scuderi et al. (22) suggest that increased levels of this cytokine may play a role in the host defense mechanism against parasitic infections. Girardin et al. (12) reported that increased serum TNF $\alpha$  levels correlated with the number of risk factors involved in children with gram-negative sepsis and purpura fulminans. Elevated levels of TNF $\alpha$  were also found in individuals suffering from myocarditis (11).

Role for TNF $\alpha$  in the pathogenesis of AIDS has also been pointed out. Alveolar macrophages (AM) from HIV positive individuals with opportunistic lung infections have been shown to spontaneously produce higher levels of TNF $\alpha$  *in vitro* than those HIV positive individuals without infection and HIV negative controls (14, 16). Krishnan et al. (16) report that higher TNF $\alpha$  production by AM was associated with lower counts of pneumocystis carinii in bronchoalveolar lavage fluid, indicating that TNF $\alpha$  may play a role in the control of this infection in AIDS. Israel-Biet et al. (14) also reported in *in vitro* studies, that AM that express HIV (p24+) released significantly higher levels of TNF $\alpha$  than p24- alveolar macrophages and controls. Reddy et al. (20) found persistently elevated levels of circulating TNF $\alpha$  in HIV seropositive individuals and suggest a possible involvement of this cytokine in the development of AIDS.

Measurement of TNF $\alpha$  levels has also been shown to be useful in transplant research, where Maury et al. (18) and McLaughlin et al. (19). Both reported TNF $\alpha$  to be markedly elevated in renal allograft rejection episodes. Recent evidence has been presented on increased TNF $\alpha$  levels in Bone Marrow Transplant (BMT) (13, 21). BMT patients with major transplant related complications such as interstitial pneumonitis and severe acute graft-versus - host disease had TNF $\alpha$  levels significantly increase over controls (13).

## **2.2. Principle of the method**

A capture Antibody highly specific for TNF $\alpha$  has been coated to the wells of the microtiter strip plate provided during manufacture. Binding of TNF $\alpha$  samples and known standards to the capture antibodies and subsequent binding of the Biotinylated anti-TNF $\alpha$  secondary antibody to the analyte is completed during the same incubation period. Any excess unbound analyte and secondary antibody is removed.

The HRP conjugate solution is then added to every well including the zero wells, following incubation excess conjugate is removed by careful washing.

A chromogen substrate is added to the wells resulting in the progressive development of a blue coloured complex with the conjugate. The colour development is then stopped by the addition of acid turning the resultant final product yellow. The intensity of the produced coloured complex is directly proportional to the concentration of TNF $\alpha$  present in the samples and standards.

The absorbance of the colour complex is then measured and the generated OD values for each standard are plotted against expected concentration forming a standard curve. This standard curve can then be used to accurately determine the concentration of TNF $\alpha$  in any sample tested.

### 3. Reagents provided and reconstitution

Reagents (Store@2-8°C)	Quantity 1x48-well kit Cat no. 950.090.048	Quantity 1x96-well kit Cat no. 950.090.096	Quantity 2x96-well kit Cat no. 950.090.192	Reconstitution
Anti-TNF $\alpha$ Coated Plate	1/2	1	2	Ready to use (96-well strip pre-coated plate)
Plastic plate covers	2	2	4	n/a
TNF $\alpha$ Standard: 800 pg/ml	1	2	4	Reconstitute as directed on the vial (see Assay preparation, section 8)
Standard Diluent (Buffer)	1 (15ml)	1 (15ml)	1 (25ml)	10X concentrate, dilute in distilled water (see Assay preparation, section 8)
Standard Diluent Serum	1 (7 ml)	1 (7 ml)	2 (7 ml)	Ready to use
TNF $\alpha$ Control	1	2	4	Reconstitute as directed on the vial (see Assay preparation, section 8)
Biotinylated Anti-TNF $\alpha$	1 (0.4ml)	1 (0.4ml)	2 (0.4ml)	Dilute in Biotinylated Antibody Diluent (see Assay preparation, section 8)
Biotinylated Antibody Diluent	1 (7ml)	1 (7ml)	1 (13ml)	Ready to use
Streptavidin-HRP	1 (5 $\mu$ l)	2 (5 $\mu$ l)	4 (5 $\mu$ l)	Add 0.5ml of Streptavidin-HRP Diluent prior to use (see Assay preparation, section 8)
Streptavidin-HRP Diluent	1 (12ml)	1 (12ml)	1 (23ml)	Ready to use
Wash Buffer	1 (10ml)	1 (10ml)	2 (10ml)	200X concentrate dilute in distilled water (see Assay preparation, section 8)
TMB Substrate	1 (11ml)	1 (11ml)	1 (24ml)	Ready to use
H <sub>2</sub> SO <sub>4</sub> Stop Reagent	1 (11ml)	1 (11ml)	2 (11ml)	Ready to use

### 4. Materials required but not provided

- Microtiter plate reader fitted with appropriate filters (450 nm required with optional 620 nm reference filter)
- Microtiter plate washer or wash bottle
- 10, 50, 100, 200 and 1,000 $\mu$ l adjustable single channel micropipettes with disposable tips
- 50-300 $\mu$ l multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

## 5. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

**Wash Buffer 1X:** Once prepared, store at 2-8°C for up to 1 week.

**Standard Diluent Buffer 1X:** Once prepared, store at 2-8°C for up to 1 week.

**Reconstituted Standard/Control:** Once prepared use immediately and do not store.

**Diluted Biotinylated Anti-TNF $\alpha$ :** Once prepared use immediately and do not store.

**Diluted Streptavidin-HRP:** Once prepared use immediately and do not store.

## 6. Specimen collection, processing & storage

Cell culture supernatants, human serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

**Cell culture supernatants:** Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

**Serum:** Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. Following clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

**Plasma:** EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

**Storage:** If not analysed shortly after collection, samples should be aliquoted (250-500 $\mu$ l) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

**Recommendation:** Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

## 7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g. CDC/NIH Health manual : "Biosafety in Microbiological and Biomedical Laboratories" 1984.
- Laboratory gloves should be worn at all times.
- Avoid any skin contact with H<sub>2</sub>SO<sub>4</sub> and TMB. In case of contact, wash thoroughly with water.
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
- Do not pipette by mouth.
- When not in use, kit components should be stored refrigerated as indicated on vials or bottles labels.
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use.
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration.
- Cover or cap all reagents when not in use.
- Do not mix or interchange reagents between different lots.
- Do not use reagents beyond the expiration date of the kit.
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H<sub>2</sub>SO<sub>4</sub> and TMB Substrate solutions, avoid pipettes with metal parts.
- Use a clean plastic container to prepare the washing solution.
- Thoroughly mix the reagents and samples before use by agitation or swirling.
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
- The TMB Substrate solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB Substrate solution with metal to prevent colour development. Warning TMB Substrate is toxic avoid direct contact with hands. Dispose off properly.
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbances within 1 hour after completion of the assay.
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells.
- Follow incubation times described in the assay procedure.
- Dispense the TMB Substrate within 15 min of the washing of the microtiter plate.

## 8. Assay Preparation

Bring all reagents to room temperature before use

### 8.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard, zero and control should be tested **in duplicate**. Remove sufficient microwell strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

**Example plate layout** (example shown for a 6 point standard curve)

	Standards / Controls		Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
A	800	800										
B	400	400										
C	200	200										
D	100	100										
E	50	50										
F	25	25										
G	0	0										
H	Ctrl	Ctrl										

*All remaining empty wells can be used to test samples in duplicate*

### 8.2. Preparation of Wash Buffer

If crystals have formed in the concentrate Wash Buffer, warm it gently until complete dissolution.

Dilute the (200X) concentrate Wash Buffer 200 fold with distilled water to give a 1X working solution. Pour entire contents (10 ml) of the concentrate Wash Buffer into a clean 2,000 ml graduated cylinder. Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2°-25°C.

### 8.3. Preparation of Standard Diluent Buffer 1X

If crystals have formed in the concentrate Standard Diluent, warm it gently until complete dissolution.

Dilute the (10X) concentrate Standard Diluent 10 fold with distilled water to give a 1X working solution. Pour entire contents of the concentrate Standard Diluent into a clean appropriate graduated cylinder. Bring to final volume with glass-distilled or deionized water. Transfer to a clean wash bottle and store at 2°-25°C. Please see example volumes below:

Standard Diluent concentrate (ml)	Distilled water (ml)
15	135
25	225



#### 8.4. Preparation of Standard

Depending on the type of samples you are assaying, the kit may include two Standard Diluents. Because biological fluids might contain proteases or cytokine-binding proteins that could modify the recognition of the cytokine you want to measure, you should reconstitute standard vials with the most appropriate Standard Diluent.

For **serum and plasma** samples: use Standard Diluent - Serum

For **cell culture supernatants**: use Standard Diluent Buffer 1X

Standard vials must be reconstituted with the volume of Standard Diluent shown on the vial immediately prior to use. This reconstitution gives a stock solution of 800pg/ml of TNF $\alpha$ . Mix the reconstituted standard gently by inversion only. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 800 to 25 pg/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200 $\mu$ l of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 800 pg/ml.
- Add 100 $\mu$ l of Standard Diluent to the remaining standard wells B1 and B2 to F1 and F2.
- Transfer 100 $\mu$ l from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells.
- Continue this 1:1 dilution using 100 $\mu$ l from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 800 pg/ml to 25 pg/ml.
- Discard 100 $\mu$ l from the final wells of the standard curve (F1 and F2).

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred into the relevant wells.

#### 8.5. Preparation of Control

Freeze-dried control vials should also be reconstituted with the most appropriate Standard Diluent to your samples.

For **serum and plasma** samples: use Standard Diluent - Serum

For **cells culture supernatants**: use Standard Diluent Buffer 1X

The supplied Control must be reconstituted with the volume of Standard Diluent indicated on the vial. Reconstitution of the freeze-dried material with the indicated volume, will give a solution at the concentration stated on the vial. Do not store after use.

#### 8.6. Preparation of Biotinylated Anti-TNF $\alpha$

It is recommended this reagent is prepared immediately before use. Dilute the Biotinylated Anti-TNF $\alpha$  with the Biotinylated Antibody Diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number of wells required	Biotinylated Antibody ( $\mu$ l)	Biotinylated Antibody Diluent ( $\mu$ l)
16	40	1060
24	60	1590
32	80	2120
48	120	3180
96	240	6360

## 8.7. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute the 5 $\mu$ l vial with 0.5ml of Streptavidin-HRP Diluent **immediately before use**. Do not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of wells required	Streptavidin-HRP ( $\mu$ l)	Streptavidin-HRP Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

## 9. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use.

Prepare all reagents as shown in section 8.

**Note:** final preparation of **Biotinylated Antibody** (section 8.6) and **Streptavidin-HRP** (section 8.7) should occur immediately before use.

Assay Step		Details
1.	Addition	<b>Prepare standard curve</b> as shown in section 8.4 above and add in duplicate to appropriate wells
2.	Addition	Add 100µl of each <b>Sample, Control and zero (appropriate Standard Diluent)</b> in duplicate to appropriate number of wells
3.	Addition	Add 50µl of diluted <b>Biotinylated Anti-TNF<math>\alpha</math></b> to all wells
4.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for <b>3 hours</b>
5.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of <b>1x Wash Buffer</b> into each well c) Aspirate the contents of each well d) Repeat step b and c another two times
6.	Addition	Add 100µl of diluted <b>Streptavidin-HRP</b> solution into all wells
7.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for <b>30 min</b>
8.	Wash	Repeat wash step 5.
9.	Addition	Add 100µl of ready-to-use <b>TMB Substrate</b> into all wells
10.	Incubation	Incubate in the dark for <b>12-15 minutes*</b> at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil.
11.	Addition	Add 100µl of <b>H<sub>2</sub>SO<sub>4</sub> Stop Reagent</b> into all wells
<p><b>Read the absorbance</b> value of each well (immediately after step 11.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm as the reference wave length (610 nm to 650 nm is acceptable).</p>		

*\* Incubation time of the TMB substrate is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range.*

## 10. Data Analysis


Calculate the average absorbance values for each set of duplicate standards, control and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding TNF $\alpha$  standard concentration on the horizontal axis.

The amount of TNF $\alpha$  in each sample is determined by extrapolating OD values against TNF $\alpha$  standard concentrations using the standard curve.

### Example TNF $\alpha$ Standard curve

Standard	TNF $\alpha$ Conc (pg/ml)	OD (450nm) mean	CV (%)
1	800	1.883	3.7
2	400	1.076	10.8
3	200	0.724	4.3
4	100	0.43	7.4
5	50	0.277	0.3
6	25	0.18	10.2
zero	0	0.102	4.2



**Note:** curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

## 11. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard Diluent Buffer or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Wash Buffer, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore **a fresh standard curve must be prepared and run for every assay.**

## 12. Performance Characteristics

### 12.1. Sensitivity

The sensitivity or minimum detectable dose of TNF $\alpha$  using this Diaclone Human TNF $\alpha$  ELISA kit was found to be **8pg/ml**. This was determined by adding 3 standard deviations to the mean OD obtained when the zero standard was assayed 40 times.

### 12.2. Specificity

The assay recognizes both natural and recombinant human TNF $\alpha$ . To define the specificity of this ELISA several proteins were tested for cross reactivity. There was no cross reactivity observed for any protein tested: IL-1 $\beta$ , IL-6, IL-12, IL-4, IL-2, IFN $\gamma$ , IL-10, IL-8, and IL-13.

### 12.3. Precision

#### Intra-assay

Reproducibility within the assay was evaluated in three independent experiments. Each assay was carried out with 6 replicates (3 duplicates) of samples containing different concentrations of TNF $\alpha$ : 3 in human pooled Serum and 2 in Culture Media. Data below show the mean TNF $\alpha$  concentration and the coefficient of variation for each sample.

**The calculated overall coefficient of variation was 3.2%.**

Session	Sample	Mean TNF $\alpha$ pg/ml	SD	CV%
Session 1	Sample 1	829.33	44.99	5.4
	Sample 2	529.33	10.60	2.0
	Sample 3	201.00	2.00	1.0
	Sample 4	182.33	7.57	4.2
	Sample 5	104.67	1.53	1.5
Session 2	Sample 1	807.00	14.80	1.8
	Sample 2	455.33	12.74	2.8
	Sample 3	171.67	9.07	5.3
	Sample 4	158.00	8.19	5.2
	Sample 5	102.67	4.73	4.6
Session 3	Sample 1	833.00	10.39	1.2
	Sample 2	489.67	12.66	2.6
	Sample 3	172.67	2.52	1.5
	Sample 4	186.67	2.52	1.3
	Sample 5	84.00	6.56	7.8

### Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in three independent experiments by two analysts. Each assay was carried out with 6 replicates (3 duplicates) of samples containing different concentrations of TNF $\alpha$ : 3 in human pooled Serum and 2 in Culture Media. Data below show the mean TNF $\alpha$  concentration and the coefficient of variation for each sample.

**The calculated overall coefficient of variation was 10.9%.**

	<i>Sample 1</i>	<i>Sample 2</i>	<i>Sample 3</i>	<i>Sample 4</i>	<i>Sample 5</i>
<b>Mean</b> TNF $\alpha$ pg/ml	815	470	167	158	87
<b>SD</b>	31	35	19	25	14
<b>CV%</b>	<b>3.8</b>	<b>7.5</b>	<b>11.5</b>	<b>15.9</b>	<b>16.1</b>

### 12.4. Dilution Parallelism

Four human pooled serum samples with different levels of TNF $\alpha$  were analysed at different serial two fold dilutions (1:2 to 1:8) with four replicates each.

Recoveries ranged from 97 to 120% with an overall **mean recovery of 107%**.

### 12.5. Spike Recovery

The spike recovery was evaluated by spiking 3 concentrations of TNF $\alpha$  in human serum in 2 separate experiments.

Recoveries ranged from 74 to 90% with an overall **mean recovery of 81%**.

### 12.6. Stability

#### Storage Stability

Aliquots of spiked serum and spiked medium were stored at  $-20^{\circ}\text{C}$ ,  $+2-8^{\circ}\text{C}$ , room temperature (RT) and at  $37^{\circ}\text{C}$  and the TNF $\alpha$  level determined after 24h. There was no significant loss of TNF $\alpha$  reactivity during storage at  $2-8^{\circ}\text{C}$ . However there is a little loss when stored at RT and a significant loss of reactivity when stored at  $37^{\circ}\text{C}$ .

#### Freeze-thaw Stability

Aliquots of spiked serum and spiked medium were stored frozen at  $-20^{\circ}\text{C}$  and thawed up to 5 times and the TNF $\alpha$  level was determined. There was no significant loss of TNF $\alpha$  reactivity after 5 cycles of freezing and thawing.

### 12.7. Expected serum values

A panel of 50 human sera was tested for TNF $\alpha$ . All were below the detection level of 8pg/ml.

### 12.8. Standard Calibration

This immunoassay is calibrated against the International Reference Standard NIBSC 87/650. NIBSC 87/650 is quantitated in International Units (IU).

It has been calculated that 1IU NIBSC correspond to 75pg Diaclone TNF $\alpha$ .

### 13. Bibliography

1. Aderka D., et al (1992). J. Exp. Med. 175, 323.
2. Adolf G., and Apfler I. (1991). J. Immunol. Methods 143, 127.
3. Alvaro-Garcia J. M., et al. (1990). J. Clin. Invest. 86, 1790.
4. Beutler B., et al. (1988). Endo. Rev. 9, 57.
5. Cerdan C., et al. (1991). J. Immunol. 146, 560.
6. Chin J. E., et al. (1990). Arthr. Rheum. 33, 162.
7. Cope A. P., et al. (1992). Arthr. Rheu. 35, 1160.
8. Digel W., et al. (1992). J. Clin. Invest 89, 1690.
9. Economou J. S., et al. (1989). Immunol. 67, 514.
10. Engelberts I., et al. (1991). Lancet 338, 515.
11. Gaumond B., et al. (1988). Presented at the 88th Annual Meeting of the American Society for Microbiology.
12. Girardin E., et al. (1988). New Eng. J. Med. 319, 397.
13. Holler E., et al. (1990). Blood 75, 1011.
14. Israel-Biet D., et al. (1991). J. Immunol. 147, 490
15. Janssen O., et al. (1988). J. Immunol. 140, 125.
16. Krishnan V. L., et al. (1990). Clin. Exp. Immunol. 80, 156.
17. Maury C. P. J. (1986). Acta Med. Scan. 220, 387.
18. Maury P. J., et al. (1987). J. Exp. Med. 166, 1137.
19. McLaughlin P. J., et al. (1991). Transplantation 51, 1225.
20. Reddy M. M., et al. (1988). J. Acq. Imm. Def. Synd. 1, 436.
21. Sardas O. S., et al. (1990). Blood 76, 2639.
22. Scuderi P., et al. (1986). Lancet, December 13, 1364.
23. Smith M. R., et al. (1990). J. Immunol. 144, 560.
24. VanZee K. J., et al. (1992). Proc. Natl. Acad. Sci. USA. 89, 4845.
25. Waage A., et al. (1987). Lancet, February 14, 355.

### 14. Diaclone Human TNF $\alpha$ ELISA references

1. Acar, L. et al.,Balkan Med J. 2018 Jan 20;35(1):30-35.
2. Agahi, A. et al., Front Neurol. 2018 Aug 15;9:662
3. Akbari, F. et al., Iran J Neurol.,2016; 15(2): 75-9.
4. Akbarpour, M.,Biol Sport,2013;30(1): 21-7
5. Akram Kooshki, A. et al.,Glob J Health Sci.,2015; 7(7 Spec No): 1-5
6. Angelot, F. et al., Haematologica,2009; 94(11): 1502-1512.
7. Anim-Nyame, N. et al.,Cardiovasc Res.,2003; 58(1): 162-169.
8. Arduise, C. et al., J. Immunol.,2008; 181(10): 7002-7013.
9. Ashraf, H. et al., Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):751-756.
10. Azadbakht, L. et al., Diabetes Care,2007;30(4):967-73
11. Badoual, C. et al., Cancer Res.,2008; 68(10): 3907-3914.
12. Barska,K. et al.,PLoS One, 2017; 12(7): e0181533.
13. Bielecka-Dabrowa, A. et al.,Int J Mol Sci.,2015; 16(5): 10715-33
14. Bielecka-Dabrowa, A. et al.,Sci Rep., 2017 Aug 21;7(1):8974.
15. Bielecka-Dabrowa, A. et al.,Sci Rep.,2015 Mar 9;5:8916.
16. Biswas, S. et al.,Korean J Intern Med.,2010; 25(1): 44-50
17. Brezáni, V. et al.,Viruses. 2018 Jul 6;10(7). pii: E360.
18. Busquets-Cortés,C. et al., Nutrients. 2018 Dec 5;10(12). pii: E1920.
19. Capo, X. et al., Nutrients,2016; 8(10).
20. Capo, X. et al.,Oxid Med Cell Longev.,2015: 187849
21. Chabbert-de-Ponnat I et al, Int Immunol. 2005 Apr;17(4):439-47
22. Chavushyan, A. et al., Schizophr Res Treatment, 2013: 125264
23. Corvaisier, M. et al., PLoS Biol.,2012;10(9): e1001395
24. Cot, M. et al.,PLoS One,2011; 6(10): e26316
25. Cunin, P. et al., J. Immunol.,2011;186(7): 4175-4182.
26. Cutolo M. et al., Ann. Rheum. Dis, 2005; 64(2): 212 – 216

27. Cutolo M. et al., *Ann. Rheum. Dis*, 2005; 65(6): 728-35
28. Cutolo, M. et al., *Arthritis Res Ther.*,2009;11(6): R176
29. Driss, V. et al., *Blood*,2009; 113(14): 3235-3244.
30. Eilertsen, G. O. et al., *Lupus*,2011 ; 20(6): 607-613.
31. Engelmann, R. et al., *Rheumatology*,2015 ; 54(3): 545-553
32. Fernandez-Yunquera, A. et al., *World J Transplant*,2014; 4(2): 133-40
33. Forsbach, A. et al., *J. Immunol.*,2008;180(6): 3729-3738.
34. Fu, J. F. et al.,*World J Gastroenterol.*,2009 ; 15(8): 912-8
35. Garcimartin, A. et al.,*BMC Complement Altern Med.*,2014; 14: 384
36. Gautam, A. et al. , *World J Diabetes*,2017; 8(2): 66-73
37. Giamarellos-Bourboulis, E. J. et al., *Crit Care*,2006; 10(3): R76
38. Girard M. et al., *Int. J. Parasitol.*, 2003; 33(7): 713 – 720
39. Gironella, M. et al., *Gut* ,2005;54(9): 1244-53.
40. Giuffrida, M. J. et al., *Influenza Other Respir Viruses*,2014; 8(1): 116-22
41. Gopas, J. et al., *Cell Death Dis.*,2016; 7(11): e2457
42. Goswami, B. et al., *Cardiovasc J Afr.*,2010; 21(2):103-8
43. Gupta, S. K. et al., *Invest. Ophthalmol. Vis. Sci.*,2008; 49(9): 4036-4040.
44. Hamdi, H. et al., *Blood*,2007;110(1):211-219
45. Hatzfeld-Charbonnier, A. S. et al., *J Leukoc Biol.*,2007;81: 1179 – 1187
46. Helbok, R. et al., *Am J Trop Med Hyg.*,2003; 68(3): 372-5.
47. Hohn, H. et al., *Clin Exp Immunol.*,2003; 131(1): 102-10
48. Iida, K. et al., *Oncol Lett.* 2019 Apr;17(4):4004-4010.
49. Jain, V. et al., *Indian J Med Res.* 2018 Sep; 148(3): 291–301.
50. Kashyap, B. et al., *J Trop Pediatr.*, 2011:fmr093
51. Keller, M. et al., *J. Immunol.*,2005; 175(11): 7678-86.
52. Kerr J. et al., *J. Gen. Virol.*, 2001; 82(Pt 12): 3011-3019
53. Kothny-Wilkes G. et al., *J. Biol. Chem.*, 1999; 274(41): 28916 – 28921
54. Koussoulas, V. et al.,*World J Gastroenterol.*,2006; 12(41): 6711-4
55. Kruger, K. et al., *J Appl Physiol.*,2011; 110(5): 1226-1232.
56. Kulkarni, R. et al., *J Clin Diagn Res.*,2013; 7(10): 2140-2
57. Kumpf, O. et al. ,*Crit Care*,2010; 14(3): R103.
58. Kurowski, M. et al.,*Arch Med Sci.* 2018 Jan;14(1):60-68.
59. Kwon K.Y. et al., *J. Korean Med. Sci.*, 2001; 16(6): 774 – 780
60. Kyriakopoulou, M. et al., *Mediators Inflamm.*, 2008: 450196.
61. Labeta, M. O. et al., *J Exp Med.*,2000; 191(10): 1807-12.
62. Lal, S. et al., *Sci Rep.* 2018 Jun 14;8(1):9109.
63. Latz E. et al., *J. Biol. Chem.*, 2002; 277(49): 47834 – 47843
64. Le Meur Y. et al., *Nephrol. Dial. Transplant.*, 1999; 14(10) : 2420 – 2426
65. Legrand, F. et al., *J. Immunol.*, 2010; 185 (12): 7443-7451
66. Legrand, F. et al.,*PLoS One*,2009;4(6): e5926
67. Lehner, M. et al., *J. Leukoc. Biol.*,2008; 83: 883 – 893
68. Lelievre, E. et al., *Cytokine*,1998;10(11): 831-40.
69. Lewis, S. et al.,*Respir Res.*,2009; 10: 44
70. Liao, B. et al., *Emerg Microbes Infect.*,2015;4(4): e24
71. Lindqvist, C. A. et al., *Immunology*,2010;133(3): 296-306.
72. Loo, W. T. et al., *J Transl Med.*,2012;10 Suppl 1: S8
73. Madempudi, R.S. et al.,*Sci Rep.* 2019 Aug 21;9(1):12210.
74. Mahalle, N. et al., *Indian J Endocrinol Metab.*,2013; 17(5): 844-50
75. Mahalle, N. et al., *Indian J Endocrinol Metab.*,2014;18(5): 708-14
76. Mahalle, N. et al.,*Ann Med Health Sci Res.*,2014;4(5): 706-12
77. Mahalle, N. et al.,*Indian J Endocrinol Metab.*,2014 ;18(1): 48-55
78. Mazurkiewicz, P. et al.,*Mol Microbiol.*,2008; 67(6): 1371-83.
79. Miot, C. et al., *Gut*,2014: gutjnl-2013-306604
80. Misra, A. & Trivedi, A., *Cancer Med.* 2018 Feb; 7 (Suppl 1): 5–58
81. Mohamed, H. S. and M. M. Meguid, *Saudi J Anaesth.*,2017;11(1): 9-14.
82. Molteni, M. et al.,*Toxins (Basel).* 2018 Jul 16;10(7). pii: E290
83. Mukhopadhyay, B. et al.,*Diagn Res* 10(2): BC08-10.
84. Mushtaq, R. et al.,*Pak J Med Sci.* 2019 Jan-Feb;35(1):77-81.
85. Nagao, Y. et al., *Malar J.*,2008; 7: 113.



86. Nebor, D. et al., *Haematologica*,2011;96(11):1589-1594
87. Niemand C. et al., *J. Immunol.*, 2003; 170(6): 3263 – 3272
88. Onambebe-Pearson, G. L. et al., *Age (Dordr)*,2010; 32(2): 125-38
89. Onambebe-Pearson, G. L. et al., *Age (Dordr)*,2010; 32(2): 139-53
90. Paduch, R. and A. Wozniak, *J Ophthalmic Vis Res.*,2015; 10(3): 229-37
91. Paduch, R. et al.,*Balkan Med J.*,2014 ;31(1): 29-36
92. Palempalli, U. D. et al., *Biochem J.*,2009; 419(2): 401-9
93. Pelekanou, A. et al., *Crit Care*,2009 ;13(6): R172
94. Perez S A. et al., *Blood*, 2003; 101(9): 3444 – 3450
95. Perez S. A. et al., *Blood*, 2005; 106(1):158 – 166
96. Perez, S. A. et al., *Int Immunol.*,2006; 18(1): 49-58.
97. Plant, L. J. and A. B. Jonsson, *Infect Immun.*,2006; 74(1): 442-8.
98. Polz-Dacewicz, M. et al., *Infect Agent Cancer*,2016; 11: 45.
99. Pritchard, J. et al., *Neurology*,2003; 61(9): 1282-4.
100. Rajappa, M. et al., *Angiology*,2009; 60(4): 419-426.
101. Rana, A. et al.,*Lupus*,2012; 21(10): 1105-1112
102. Rana, S. V. et al., *J Crohns Colitis*,2014 ; 8(8): 859-865
103. Rasool, M. et al., *PLoS One*,2016; 11(11): e0167149
104. Rasool, M. et al.,*Saudi J Biol Sci.* 2018 Dec;25(8): 1724-1728.
105. Ren, J. G. et al.,*Journal of Dental Research*,2015: 0022034515592593
106. Robertson, M. D. et al., *J. Clin. Endocrinol. Metab.*,2012; 97(9): 3326-3332.
107. Rodríguez-Luna, A. et al., *Mar Drugs.* 2018 Oct 10;16(10). pii: E378.
108. Routsis, C. et al.,*Clin Exp Immunol.*,2005;142(1): 62-7.
109. Rytönen, A. et al., *Proc Natl Acad Sci.*,2007;104(9): 3502-7.
110. Salem, M. et al.,*Clin Exp Immunol.*,2015 ; 179(3): 426-34
111. Salem, M. et al.,*Clin Transl Gastroenterol.*,2015; 6: e12
112. Salmeri, F. M. et al.,*Reproductive Sciences*,2014: 1933719114536472
113. Schaerli P. et al., *J. immunol.*, 2004; 173(3): 2151 – 2158
114. Shadman, Z. et al., *J Diabetes Metab Disord.*,2013;12(1): 42
115. Shete, S.U. et al.,*J Educ Health Promot.* 2017 Aug 9;6:76
116. Soliman, A.H., *Asian Pac J Cancer Prev.* 2016 Dec 1;17(12):5273-5280.
117. Spanou, Z. et al., *J Am Soc Nephrol.*,2006; 17(10): 2919-27.
118. Suzuki, N. et al., *Tob Induc Dis.*,2016; 14: 20.
119. Szot, K. et al., *Environ Geochem Health.* 2019 Jun;41(3):1577-1582.
120. Tang, Y. et al., *Am J Trop Med Hyg.*,2008; 79(2): 154-158.
121. Tang, Y. et al.,*PLoS One*,2010; 5(12): e15631
122. Tayal, D. et al.,*Indian J Clin Biochem.*,2014; 29(2): 139-44
123. Tiwari, S. et al., *Endocr. Rev.*,2011 ;32 (03\_MeetingAbstracts): P2-100
124. Tluk, S. et al., *Int. Immunol.*,2009; 21(5): 607-619.
125. Tryniszewski, W. et al., *Acta Endocrinol (Buchar).* 2018 Oct-Dec;14(4):439-446.
126. Trznadel-Grodzka, E. et al., *Postepy Hig Med Dosw (Online)*,2012; 66: 843-7
127. Trznadel-Grodzka, E. et al., *Postepy Hig Med Dosw (Online)*,2012; 66: 848-54
128. Tsaganos, T. et al.,*BMC Infect Dis.*,2006; 6: 142.
129. Tuttolomondo, A. et al.,*PLoS One*,2016; 11(12): e0165443
130. Tyagi, A. et al.,*Indian J Crit Care Med.* 2019 Feb; 23(2): 89–94
131. Uchiyama, T. et al.,*Int J Mol Sci.* 2019 Apr 22;20(8). pii: E1960.
132. Valdor, R. et al.,*Oncotarget.* 2017 Aug 2;8(40):68614-68626.
133. Verghese, B. et al., *Indian J Clin Biochem.*,2011 ; 26(4): 373-7
134. Vollmer, J. et al., *J Exp Med.*,2005; 202(11): 1575-85.
135. Voskaridou, E. et al., *Blood (ASH Annual Meeting Abstracts)*,2008; 112(11): 3888
136. Walavalkar, V. et al., *Eur J Cardiothorac Surg.*,2016;49(5): 1403-1410
137. Walther, W. et al., *Mol Cancer Ther.*,2007; 6(1): 236-43.
138. Wrenger, S. et al., *J. Leukoc. Biol.*,2006; 80(3): 621-629.
139. Zaharieva, E.T. et al.,*J Diabetes Res.* 2017;2017:9016148
140. Zakerkish, M. et al., *Sci Rep.* 2019 May 13;9(1):7289.
141. Zebrowska, A. et al.,*Mediators Inflamm.*, 2014: 936545
142. Zhang, J. et al.,*Tanaffos.* 2017 Jun;16(4):260-269.
143. Zhou, C. et al., *J Neuroinflammation*,2015; 12(1): 200

## 15. Assay Summary

**Total procedure length: 3h45min**

**Add 100µl of Samples, Control and diluted Standards  
and 50µl diluted Biotinylated Antibody**



**Incubate 3 hours at room temperature**



**Wash three times**



**Add 100µl of diluted Streptavidin-HRP**



**Incubate 30 min at room temperature**



**Wash three times**



**Add 100µl of TMB Substrate  
Protect from light. Let the color develop for 12-15 min.**



**Add 100µl of Stop Reagent**



**Read Absorbance at 450 nm**

### **Products Manufactured and Distributed by:**

**Diaclone SAS**  
6 Rue Docteur Girod  
25020 Besançon Cedex  
France  
Tel +33 (0)3 81 41 38 38  
Fax +33 (0)3 81 41 36 36  
Email: [info@diaclone.com](mailto:info@diaclone.com)